ArticleCancers2025
Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConventional prognostic factors are typically assessed at diagnosis in metastatic hormone-sensitive prostate cancer (mHSPC). However, variations in vital signs and laboratory parameters occur during systemic treatment and may predict patients' prognosis and anticipate organ-specific toxicity development.
methodsThis single-center retrospective study included 363 patients with de novo mHSPC treated between 2014 and 2023. Clinical and laboratory data were systematically collected from the hospital data warehouse, from treatment initiation through the following seven months. Variations in vital parameters and blood test results were graded using CTCAE V5.0 (dynamic variables). Cox regression analyses were performed to explore the impact of dynamic variables on progression-free survival (PFS) and overall survival (OS). Machine learning (ML) models (Support Vector Classifier, Random Forest, and LGBM Classifier) were developed to predict single organ-specific toxicities and to identify good and poor responders based on 7-month PSA levels, PFS and OS. We compared ML model performance when trained only on baseline factors (static models) with those integrating variables generated by vital sign and blood test monitoring within 3 and 7 months from treatment start (dynamic models).
resultsDynamic model failed to improve the prediction of single organ-specific toxicities. Univariable Cox analysis revealed that the development of hematological, liver, and kidney-related toxicity, as well as the development of electrolyte disturbances within 3 or 7 months, was associated with shorter PFS (
conclusionsThe integration of conventional prognostic factors with the detection of significant changes in vital signs and blood tests occurring early during systemic treatment in patients with de novo mHSPC may enhance patient stratification and improve prediction of survival outcomes. Multicenter validation studies are needed to confirm these results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.